Canada markets closed

BioSyent Inc. (RX.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
7.80+0.01 (+0.13%)
At close: 03:57PM EDT
Full screen
Previous Close7.79
Bid7.80 x 0
Ask7.95 x 0
Day's Range7.79 - 7.88
52 Week Range6.76 - 10.00
Avg. Volume3,430
Market Cap96.783M
Beta (5Y Monthly)0.93
PE Ratio (TTM)16.25
EPS (TTM)0.48
Earnings DateAug 23, 2022 - Aug 29, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
  • Simply Wall St.

    BioSyent (CVE:RX) shareholders have earned a 6.8% CAGR over the last three years

    BioSyent Inc. ( CVE:RX ) shareholders might be concerned after seeing the share price drop 17% in the last quarter. In...

  • GlobeNewswire

    BioSyent Releases Financial Results for Q1 2022

    MISSISSAUGA, Ontario, May 18, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months ended March 31, 2022. Key highlights include: First quarter (Q1) 2022 Net Revenues of $7,037,411 decreased by 5% versus Q1 2021Q1 2022 Net Revenues from continuing brands (excluding discontinued Aguettant System® and Cysview® brands) decreased by 0% versus Q1 2021Q1 2022 Canadian Pharmaceutical Net Revenues of $6,318,884 increased by 1% vers

  • GlobeNewswire

    BioSyent Schedules Q1 2022 Earnings Release for May 18, 2022

    MISSISSAUGA, Ontario, May 10, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2022 on Wednesday, May 18, 2022 at 8:00am ET. A presentation on the Company’s first quarter 2022 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, B